Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4535440 | 0.91 | MAPT (0.49) | MAPTPIK3CDKMT2AMEN1LMNA | |
| SCHEMBL4635644 | 0.82 | PIK3CG (0.45) | MAPTPIK3CDTP53PIK3CG | |
| SCHEMBL4341730 | 0.80 | PIK3CD (0.49) | MAPTPIK3CDKMT2AMEN1LMNA | |
| SCHEMBL4351831 | 0.79 | MEN1 (0.47) | MAPTPIK3CDKMT2AMEN1TP53 | |
| SCHEMBL4339120 | 0.79 | PIK3CG (0.51) | MAPTPIK3CDTP53PIK3CG | |
| SCHEMBL27901645 | 0.78 | PIK3CD (0.56) | MAPTPIK3CDKMT2AMEN1TP53 | |
| SCHEMBL3690864 | 0.76 | PIK3CG (0.50) | MAPTPIK3CDTP53PIK3CG | |
| SCHEMBL4019884 | 0.76 | MAPT (0.54) | MAPTPIK3CDKMT2AMEN1LMNA | |
| SCHEMBL2300757 | 0.76 | PIK3CG (0.72) | MAPTPIK3CDKMT2APIK3CG | |
| SCHEMBL4481357 | 0.75 | MAPT (0.50) | MAPTKMT2AMEN1TP53GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2056829-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | Exelixis, Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |